Why Are Abbott Laboratories Shares Trading Lower?
Why Are Abbott Laboratories Shares Trading Lower?
Despite the growth in medical devices, diagnostics sales were impacted by a year-over-year decline in COVID-19 testing-related sales, which dropped to $102 million from $263 million the previous year. Overall diagnostics sales fell 5.3% to $2.19 billion. Meanwhile, nutrition sales increased 3.5% to $2.15 billion, with a 7.5% organic growth rate.Shares of Abbott Laboratories (NYSE:ABT) are trading lower on Thursday following the company's second-quarter 2024 financial results.
雅培（纽交所：ABT）的股票周四出现下跌，原因是该公司发布了2024财年第二季度财务报告。
What's Going On: Abbott reported second-quarter sales of $10.377 billion, slightly beating the $10.371 billion estimate. EPS came in at $1.14, surpassing analyst estimates of $1.10.
动态：雅培报告了第二季度销售额为103.77亿美元，略高于103.71亿美元的预期。毎股收益为1.14美元，超过了1.10美元的分析师预期。
The company also saw a 10.2% increase in sales to $4.73 billion and a 12.1% organic growth rate. This growth included double-digit gains in Diabetes Care, Electrophysiology and Structural Heart sectors.
该公司的销售额和有机增长率分别增加了10.2％至47.3亿美元和12.1％。这种增长包括糖尿病护理、电生理和结构心脏部门的两位数增长。
Despite the growth in medical devices, diagnostics sales were impacted by a year-over-year decline in COVID-19 testing-related sales, which dropped to $102 million from $263 million the previous year. Overall diagnostics sales fell 5.3% to $2.19 billion. Meanwhile, nutrition sales increased 3.5% to $2.15 billion, with a 7.5% organic growth rate.
尽管医疗设备增长走势良好，但随着新冠病毒检测相关销售从去年的2.63亿美元下降至1.02亿美元，诊断销售受到影响。总体诊断销售下降了5.3％至21.9亿美元。与此同时，营养销售额增长了3.5％至21.5亿美元，有机增长率为7.5％。
What Else: In April, Abbott received FDA approval for the Esprit below-the-knee (BTK) system, a breakthrough for peripheral artery disease treatment. In June, the company announced FDA clearance for two new over-the-counter continuous glucose monitoring systems, Lingo and Libre Rio, based on the FreeStyle Libre technology. Additionally, Abbott obtained a CE Mark for its AVEIR dual chamber leadless pacemaker system.
其他信息：4月份，雅培获得了Esprit BTK系统的FDA批准，这是外周动脉疾病治疗的突破。6月，该公司宣布根据FreeStyle Libre技术获得了两种新的非处方连续血糖监测系统Lingo和Libre Rio的FDA清除。此外，雅培获得了AVEIR双腔无导联起搏器系统的CE标志。
ABT Price Action: Abbott Laboratories shares were down by 4.32% at $100.16 according to Benzinga Pro.
ABT价格走势：根据Benzinga Pro，雅培的股票下跌了4.32％，至100.16美元。
- Nintendo Unveils Joy-Con Charging Stand For Switch
- 任天堂为Switch推出Joy-Con充电底座
Photo by solarseven on Shutterstock.
Shutterstock上solarseven拍摄的照片。